SCHEMBL2548314

SCHEMBL2548314

C#CCNC(=O)CCCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.46
TSHR P16473 4/20 0.43
EPHX2 P34913 3/20 0.42
CNR2 P34972 1/20 0.41
LMNA P02545 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ADRA1A P35348 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NFKB1 P19838 1/20 0.39
PMP22 Q01453 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26315807 0.94 HSD17B10 (0.55) CYP1A2CYP2D6MAPTCYP2C9CYP2C19
SCHEMBL26315776 0.89 EPHX2 (0.57) CYP1A2CYP2D6MAPTCYP2C9CYP2C19
SCHEMBL3494897 0.87 PHF8 (0.46) CYP1A2CYP2D6MAPTCYP2C9CYP2C19
SCHEMBL10021727 0.85 FAAH (0.50) CYP1A2CYP2D6MAPTCYP2C9CYP2C19
SCHEMBL25490376 0.83 CNR2 (0.44) CYP1A2CYP2D6MAPTTSHRCNR2
SCHEMBL22508744 0.82 HSD17B10 (0.47) CYP1A2CYP2D6MAPTCYP2C9CYP2C19
SCHEMBL22508727 0.82 TSHR (0.51) CYP1A2CYP2D6MAPTCYP2C9CYP2C19
SCHEMBL21291251 0.82 NOD1 (0.40)
SCHEMBL12362917 0.81 CNR2 (0.52) CNR2L3MBTL1
SCHEMBL26616605 0.81 CYP1A2 (0.49) CYP1A2CYP2D6MAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025093800-A1 COMPOUNDS AND ANTIBODIES FOR THE IMMUNODETECTION OF CITRININ UNIVERSITAT DE VALÈNCIA (ES) 2025-05-08 WO disclosed
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ARGORNA PHARMACEUTICALS CO., LTD. (CN) 2023-09-21 US disclosed
WO-2023121753-A1 BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-06-29 WO disclosed
US-9242010-B2 Living copolymer-protein/peptide hybrids for biomedical applications RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2016-01-26 US disclosed
US-9242010-B2 Living copolymer-protein/peptide hybrids for biomedical applications RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2016-01-26 US disclosed
US-9242010-B2 Living copolymer-protein/peptide hybrids for biomedical applications RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2016-01-26 US disclosed
US-20110262991-A1 Living Copolymer-Protein/Peptide Hybrids for Biomedical Applications THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK 2011-10-27 US disclosed
US-20110262991-A1 Living Copolymer-Protein/Peptide Hybrids for Biomedical Applications THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK 2011-10-27 US disclosed
US-20110262991-A1 Living Copolymer-Protein/Peptide Hybrids for Biomedical Applications THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK 2011-10-27 US disclosed
WO-2009140683-A1 LIVING COPOLYMER PROTEIN/PEPTIDE HYBRIDS FOR BIOMEDICAL APPLICATIONS RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2009-11-19 WO disclosed
WO-2009140683-A1 LIVING COPOLYMER PROTEIN/PEPTIDE HYBRIDS FOR BIOMEDICAL APPLICATIONS RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ASGR1, HAVCR2, SLC10A1 CYP1A2 2665/4885CYP2D6 1274/4885MAPT 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.